A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Phase 1 Terminated 11 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.

Timeline

Start: 2021-04-08
Primary completion: 2022-11-01
Completion: 2022-11-01

Outcome

Outcome not reported

Stopped (Business): “R\&d strategy adjustment”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1916	Unknown	—	—
Background	SHR-1906	Unknown	—	—

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Summary

Timeline

Outcome

Drugs

Indications